Item
1. Financial Statements.
My
Size Inc. and Subsidiaries
Condensed
Consolidated
Interim
Financial
Statements
As
of September 30, 2022
(unaudited)
U.S.
Dollars in Thousands
MY
SIZE, INC. AND ITS SUBSIDIARIES
Condensed
Consolidated Interim Financial Statements as of September 30, 2022 (Unaudited)
Contents
MY
SIZE, INC. AND ITS SUBSIDIARIES
Condensed
Consolidated Interim Balance Sheets (Unaudited)
U.S.
dollars in thousands (except share data and per share data)
The
accompanying notes are an integral part of the condensed consolidated interim financial statements.
MY
SIZE, INC. AND ITS SUBSIDIARIES
Condensed
Consolidated Interim Statements of Comprehensive Loss (Unaudited)
U.S.
dollars in thousands (except share data and per share data)
The
accompanying notes are an integral part of the interim condensed consolidated financial statements
MY
SIZE, INC. AND ITS SUBSIDIARIES
Condensed
Consolidated Interim Statements of Changes in Stockholders’ Equity (Unaudited)
U.S.
dollars in thousands (except share data and per share data)
| |
Common stock | | |
Additional paid-in | | |
Accumulated other comprehensive | | |
Accumulated | | |
Total stockholders’ | |
| |
Number | | |
Amount | | |
capital | | |
loss | | |
deficit | | |
equity | |
| |
| | |
| | |
| | |
| | |
| | |
| |
Balance as of January 1, 2021 | |
| 7,232,836 | | |
| 7 | | |
| 37,164 | | |
| (424 | ) | |
| (34,671 | ) | |
| 2,076 | |
Stock-based compensation related to options granted to employees and consultants | |
| - | | |
| - | | |
| 350 | | |
| - | | |
| - | | |
| 350 | |
Exercise of options granted to employees (*) | |
| 4,458 | | |
| -* | | |
| - | | |
| - | | |
| - | | |
| - | |
Restricted shares issued to shareholder | |
| 2,500,000 | | |
| 3 | | |
| 2,615 | | |
| - | | |
| - | | |
| 2,618 | |
Issuance of shares, net of issuance cost of $768 | |
| 4,580,491 | | |
| 4 | | |
| 5,031 | | |
| - | | |
| - | | |
| 5,035 | |
Exercise of warrants | |
| 751,802 | | |
| 1 | | |
| 821 | | |
| - | | |
| - | | |
| 822 | |
Total comprehensive loss | |
| - | | |
| - | | |
| - | | |
| (8 | ) | |
| (7,805 | ) | |
| (7,813 | ) |
Balance as of September 30, 2021 | |
| 15,069,587 | | |
| 15 | | |
| 45,981 | | |
| (432 | ) | |
| (42,476 | ) | |
| 3,088 | |
(*) |
Represents
an amount less than $1 |
|
|
Common
stock |
|
|
Additional
paid-in |
|
|
Accumulated
other comprehensive |
|
|
Accumulated |
|
|
Total
stockholders’ |
|
|
|
Number |
|
|
Amount |
|
|
capital |
|
|
loss |
|
|
deficit |
|
|
equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance
as of July 1, 2022 |
|
|
25,551,906 |
|
|
|
26 |
|
|
|
57,048 |
|
|
|
(284 |
) |
|
|
(49,095 |
) |
|
|
7,695 |
|
Stock-based
compensation related to options granted to employees and consultants |
|
|
- |
|
|
|
- |
|
|
|
165 |
|
|
|
- |
|
|
|
- |
|
|
|
165 |
|
Issuance
of shares in Business Combination (*)
(**) |
(**) |
|
174,378 |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Issuance
of shares in Business Combination |
(**) |
|
174,378 |
|
|
|
-* |
|
|
|
-* |
|
|
|
-* |
|
|
|
-* |
|
|
|
-* |
|
Total
comprehensive loss |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(300 |
) |
|
|
(2,026 |
) |
|
|
(2,326 |
) |
Balance
as of September 30, 2022 |
|
|
25,726,284 |
|
|
|
26 |
|
|
|
57,213 |
|
|
|
(584 |
) |
|
|
(51,121 |
) |
|
|
5,534 |
|
(*) |
See
note 6 a. |
(**) |
Represents an amount less than $1 |
| |
Common stock | | |
Additional paid-in | | |
Accumulated other comprehensive | | |
Accumulated | | |
Total stockholders’ | |
| |
Number | | |
Amount | | |
capital | | |
loss | | |
deficit | | |
equity | |
| |
| | |
| | |
| | |
| | |
| | |
| |
Balance as of July 1, 2021 | |
| 15,038,327 | | |
| 15 | | |
| 45,838 | | |
| (440 | ) | |
| (40,468 | ) | |
| 4,945 | |
Stock-based compensation related to options granted to employees and consultants | |
| - | | |
| - | | |
| 118 | | |
| - | | |
| - | | |
| 118 | |
Exercise of options granted to employees * | |
| 4,458 | | |
| -* | | |
| - | | |
| - | | |
| - | | |
| - | |
Exercise of warrants | |
| 26,802 | | |
| -* | | |
| 25 | | |
| - | | |
| - | | |
| 25 | |
Total comprehensive loss | |
| - | | |
| - | | |
| - | | |
| 8 | | |
| (2,008 | ) | |
| (2,000 | ) |
Balance as of September 30, 2021 | |
| 15,069,587 | | |
| 15 | | |
| 45,981 | | |
| (432 | ) | |
| (42,476 | ) | |
| 3,088 | |
(*) |
Represents
an amount less than $1 |
The
accompanying notes are an integral part of the interim condensed consolidated financial statements
MY
SIZE, INC. AND ITS SUBSIDIARIES
Condensed
Consolidated Interim Statements of Cash Flows (Unaudited)
U.S.
dollars in thousands
(*) |
$6,310
relates to change in cash and cash equivalents and $11 to change in restricted cash. |
The
accompanying notes are an integral part of the interim condensed consolidated financial statements.
MY
SIZE, INC. AND ITS SUBSIDIARIES
Notes
to Condensed Consolidated Interim Financial Statements (Unaudited)
U.S.
dollars in thousands (except share data and per share data)
Note
1 - General
|
a. |
My
Size, Inc. is developing unique measurement technologies based on algorithms with applications
in a variety of areas, from the apparel e-commerce market to the courier services market
and to the Do It Yourself smartphone and tablet apps market. The technology is driven by
proprietary algorithms which are able to calculate and record measurements in a variety of
novel ways.
Following
the acquisition of Orgad International Marketing Ltd. (“Orgad”) in February 2022 (see note 6), the Company also operates
an omnichannel e-commerce platform.
The
Company has five subsidiaries, My Size Israel 2014 Ltd (“My Size Israel”), Topspin Medical (Israel) Ltd., and Orgad all
of which are incorporated in Israel, and My Size LLC which was incorporated in the Russian Federation and Naiz Bespoke Technologies,
S.L., a limited liability company incorporated under the laws of Spain (see note 9). References to the Company include the subsidiaries unless
the context indicates otherwise. |
|
|
|
|
b. |
During
the nine-month period ended September 30, 2022, the Company has incurred significant losses
and negative cash flows from operations and has an accumulated deficit of $51,121. The Company
has financed its operations mainly through fundraising from various investors.
The
Company’s management expects that the Company will continue to generate losses and negative cash flows from operations for
the foreseeable future. Based on the projected cash flows and cash balances as of September 30, 2022, management is of the opinion
that its existing cash will be sufficient to fund operations for a period less than 12 months. As a result, there is substantial
doubt about the Company’s ability to continue as a going concern.
Management’s
plans include the continued commercialization of the Company’s products and securing sufficient financing through the sale
of additional equity securities, debt or capital inflows from strategic partnerships. Additional funds may not be available when
the Company needs them, on terms that are acceptable to it, or at all. If the Company is unsuccessful in commercializing its products
and securing sufficient financing, it may need to cease operations.
The
financial statements include no adjustments for measurement or presentation of assets and liabilities, which may be required should
the Company fail to operate as a going concern. |
|
|
|
|
c. |
In
late 2019, a novel strain of COVID-19, also known as coronavirus, was reported in Wuhan, China. While initially the outbreak was
largely concentrated in China, it spread globally. Many countries around the world, including Israel, have from time to time implemented
significant governmental measures to control the spread of the virus, including temporary closure of businesses, severe restrictions
on travel and the movement of people, and other material limitations on the conduct of business. While the COVID-19 pandemic did
not materially adversely affect the Company’s consolidated financial results and operations during the three and nine months
ended September 30, 2022, the COVID-19 pandemic affected the Company’s operations in 2020 and 2021. The pandemic may continue
to have an impact on the Company’s business, operations, and financial results and conditions, directly and indirectly, including,
without limitation, impacts on the health of the Company’s management and employees, its operations, marketing and sales activities,
and on the overall economy. The extent to which COVID-19 impacts the Company’s operations will depend on future developments,
which are highly uncertain and cannot be predicted with confidence, including the duration and severity of the outbreak, and the
actions that may be required to contain COVID-19 or treat its impact. |
Note
2 - Significant Accounting Policies
|
a. |
Unaudited
condensed consolidated financial statements: |
|
|
|
|
|
The
accompanying unaudited condensed consolidated interim financial statements included herein have been prepared by the Company in accordance
with the rules and regulations of the United States Securities and Exchange Commission (“SEC”). The unaudited condensed
consolidated financial statements are comprised of the financial statements of the Company. In management’s opinion, the interim
financial data presented includes all adjustments necessary for a fair presentation. All intercompany accounts and transactions have
been eliminated. Certain information required by U.S. generally accepted accounting principles (“GAAP”) has been condensed
or omitted in accordance with rules and regulations of the SEC. Operating results for the nine months ended September 30, 2022 are
not necessarily indicative of the results that may be expected for any future period or for the year ending December 31, 2022. |
|
|
|
|
|
These
unaudited condensed consolidated financial statements should be read in conjunction with
the Company’s audited consolidated financial statements and the notes thereto for the
year ended December 31, 2021.
|
MY
SIZE, INC. AND ITS SUBSIDIARIES
Notes
to Condensed Consolidated Interim Financial Statements (Unaudited)
U.S.
dollars in thousands (except share data and per share data)
Note
2 - Significant Accounting Policies (cont.)
|
b. |
Significant
Accounting Policies: |
|
|
|
|
|
The
significant accounting policies followed in the preparation of these unaudited interim condensed consolidated financial statements
are identical to those applied in the preparation of the latest annual financial statements, except the following new policies which
were adopted following the business combination (see note 6): |
Inventories
are measured at the lower of cost or net realizable value. The cost of inventories comprises of the costs incurred in bringing the inventories
to their present location and condition. Net realizable value is the estimated selling price in the ordinary course of business. At the
point of the loss recognition, a new, lower-cost basis for that inventory is established, and subsequent changes in facts and circumstances
do not result in the restoration or increase in that newly established cost basis.
Since
the acquisition of Orgad (see note 6 - Business combination), the Company’s revenues are comprised of two main categories: (1)
selling products to customers, and (2) licensing cloud-enabled software subscriptions, associated software maintenance and support.
Revenue
from sale of products
Revenue
from sale of products is recognized at the time the related performance obligation is satisfied by transferring a promised good to a
customer. Revenue is recognized net of allowances for refunds and any taxes collected from customers, which are subsequently remitted
to governmental authorities. Refunds are estimated at contract inception and updated at the end of each reporting period if additional
information becomes available. Revenue is recognized when control of the product is transferred to the customer.
The
Company maintains a returns policy that allows its customers to return product within a specified period of time. The estimate of the
provision for returns is based upon historical experience with actual returns.
Revenue
from licensing
The
Company recognizes revenue in accordance with ASC Topic 606, Revenues from Contracts with Customers (“ASC 606”). A contract
with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations,
the Company can identify each party’s rights regarding the distinct goods or services to be transferred (“performance obligations”),
the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and
it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that
will be transferred to the customer.
MY
SIZE, INC. AND ITS SUBSIDIARIES
Notes
to Condensed Consolidated Interim Financial Statements (Unaudited)
U.S.
dollars in thousands (except share data and per share data)
Note
2 - Significant Accounting Policies (cont.)
Principal
versus Agent Considerations
The
Company follows the guidance provided in ASC 606 for determining whether it is a principal or an agent in arrangements with customers,
by assessing whether the nature of the Company’s promise is a performance obligation to provide the specified goods (principal)
or to arrange for those goods to be provided by the other party (agent). With regard to products being sold by Orgad through Amazon,
this determination involves judgment. The Company determined it is a principal, as it has determined that it controls the promised product
before it is transferred to the end customers, it is primarily responsible for fulfilling the promise to provide the goods, and it has
discretion in establishing prices. Therefore, the revenues are recorded on a gross basis.
The
Company applies the provisions of ASC 805, “Business Combination” and allocates the fair value of purchase consideration
to the tangible assets acquired, liabilities assumed, and intangible assets acquired based on their estimated fair values. The excess
of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill.
When determining the fair values of assets acquired and liabilities assumed, the Company estimated the future expected cash flows from
acquired platform from a market participant perspective, useful lives and discount rates. In addition, management makes significant estimates
and assumptions, which are uncertain, but believed to be reasonable.
Significant
estimates in valuing certain intangible assets include but are not limited to future expected cash flows from acquired platforms from
a market participant perspective, useful lives and discount rates. Management’s estimates of fair value are based upon assumptions
believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates.
Acquisition-related
costs are recognized separately from the acquisition and are expensed as incurred.
Goodwill
represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination.
Under ASC 350, “Intangible - Goodwill and Other”, goodwill is not amortized, but rather is subject to an annual impairment
test.
ASC
350 requires goodwill to be tested for impairment at the reporting unit level at least annually, the fourth quarter,
or between annual tests in certain circumstances, and written down when impaired. Goodwill is tested for impairment by comparing the
fair value of the reporting unit with it carrying value.
ASC
350 allows an entity to first assess qualitative factors to determine whether it is necessary
to perform the two-step quantitative goodwill impairment test. If the qualitative assessment does not result in a more likely than not
indication of impairment, no further impairment testing is required. If it does result in a more likely than not indication of impairment,
the two-step impairment test is performed. Goodwill is not deductible for income tax purposes. Goodwill is allocated to the fashion and
equipment e-commerce platform segment.
Alternatively,
ASC 350 permits an entity to bypass the qualitative assessment for any reporting unit and proceed directly to performing the first step
of the goodwill impairment test. There were no impairment charges to goodwill during the period presented.
MY
SIZE, INC. AND ITS SUBSIDIARIES
Notes
to Condensed Consolidated Interim Financial Statements (Unaudited)
U.S.
dollars in thousands (except share data and per share data)
Note
2 - Significant Accounting Policies (cont.)
Intangible
assets consist of identifiable intangible assets that the Company has acquired from previous business combinations. Intangible assets
are recorded at costs, net of accumulated amortization. The Company amortizes its intangible assets reflecting the pattern in which the
economic benefits of the intangible assets are consumed. When a pattern cannot be reliably determined, the Company uses a straight-line
amortization method.
The
estimated useful lives of the company’s intangible assets are as follows:
Schedule of Intangible Assets Estimated Useful Lives
Each
period the Company evaluates the estimated remaining useful lives of its intangible assets and whether events or changes in circumstances
warrant a revision to the remaining period of amortization
The
preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the
amounts reported and disclosed in the financial statements and the accompanying notes. Actual results could differ materially from these
estimates.
MY
SIZE, INC. AND ITS SUBSIDIARIES
Notes
to Condensed Consolidated Interim Financial Statements (Unaudited)
U.S.
dollars in thousands (except share data and per share data)
Note
3 - Financial Instruments
The
carrying amounts of cash and cash equivalents, accounts receivable, other receivables, trade payables and accounts payable approximate
their fair value due to the short-term maturities of such instruments.
The
Company holds share certificates in iMine Corporation (“iMine”) formerly known as Diamante Minerals, Inc., a publicly traded
company on the OTCQB.
Due
to sales restrictions on the sale of the iMine shares, the fair value of the shares was measured on the basis of the quoted market price
for an otherwise identical unrestricted equity instrument of the same issuer that trades in a public market, adjusted to reflect the
effect of the sales restrictions and is therefore, ranked as Level 2 assets.
Schedule of Significant Assets and Liabilities Measured at Fair Value on Recurring Basis
| |
September 30, 2022 | |
| |
Fair value hierarchy | |
| |
Level 1 | | |
Level 2 | | |
Level 3 | |
Financial assets | |
| | | |
| | | |
| | |
| |
| | | |
| | | |
| | |
Investment in marketable securities (*) | |
| - | | |
| 80 | | |
| - | |
| |
September 30, 2022 | |
| |
Fair value hierarchy | |
| |
Level 1 | | |
Level 2 | | |
Level 3 | |
Financial liabilities | |
| | | |
| | | |
| | |
| |
| | | |
| | | |
| | |
Derivatives | |
| - | | |
| 28 | | |
| - | |
MY
SIZE, INC. AND ITS SUBSIDIARIES
Notes
to Condensed Consolidated Interim Financial Statements (Unaudited)
U.S.
dollars in thousands (except share data and per share data)
Note
3 - Financial Instruments (Cont.)
| |
December 31, 2021 | |
| |
Fair value hierarchy | |
| |
Level 1 | | |
Level 2 | | |
Level 3 | |
Financial assets | |
| | | |
| | | |
| | |
| |
| | | |
| | | |
| | |
Investment in marketable securities (*) | |
| - | | |
| 108 | | |
| - | |
(*) |
For
the nine and three-month periods ended September 30, 2022 and 2021, the recognized gain (loss) (based on quoted market prices with
a discount due to security restrictions on iMine shares) of the marketable securities was ($28) and $(17), and $46 and $24 respectively. |
| |
December 31, 2021 | |
| |
Fair value hierarchy | |
| |
Level 1 | | |
Level 2 | | |
Level 3 | |
Financial liabilities | |
| | | |
| | | |
| | |
| |
| | | |
| | | |
| | |
Derivatives | |
| - | | |
| 2 | | |
| - | |
Note
4 - Stock Based Compensation
The
stock-based expense equity awards recognized in the financial statements for services received is related to Cost of Revenues, Research
and Development, Sales and Marketing and General and Administrative expenses as shown in the following table:
Schedule
of Stock Based Compensation Expenses
| |
2022 | | |
2021 | | |
2022 | | |
|
| |
Nine months ended September 30, | | |
Three months ended September 30, | |
| |
2022 | | |
2021 | | |
2022 | | |
2021 | |
| |
| | |
| | |
| | |
| |
Stock-based compensation expense – Cost of revenues | |
| 67 | | |
| - | | |
| 39 | | |
| - | |
Stock-based compensation expense - Research and development | |
| 22 | | |
| 103 | | |
| 4 | | |
| 33 | |
Stock-based compensation expense - Sales and marketing | |
| 115 | | |
| 164 | | |
| 57 | | |
| 71 | |
Stock-based compensation expense - General and administrative | |
| 123 | | |
| 83 | | |
| 65 | | |
| 14 | |
| |
| | | |
| | | |
| | | |
| | |
Stock-based compensation
expense | |
| 327 | | |
| 350 | | |
| 165 | | |
| 118 | |
Options
issued to consultants:
|
|
In
July 2019, the Company entered into a three-year agreement with a consultant (“Consultant14”) to provide services to
the Company including assisting the Company to promote, market and sell the Company’s technology to potential customers. Pursuant
to such agreement and in partial consideration for such consulting services, the Company agreed to issue to Consultant14 options
to purchase up to 2,667 shares of the Company’s common stock upon execution of the agreement. The options are exercisable at
$15.00 per share and shall vest in 3 equal instalments every twelve months starting July 2019. Unexercised options shall expire 4
years from the effective date. |
MY
SIZE, INC. AND ITS SUBSIDIARIES
Notes
to Condensed Consolidated Interim Financial Statements (Unaudited)
U.S.
dollars in thousands (except share data and per share data)
Note
4 - Stock Based Compensation (Cont.)
|
|
In
addition, the Company agreed to issue to Consultant14 options to purchase up to 22,233 shares of the Company’s common stock
upon execution of the agreement. The options are exercisable at $1.08 per share and shall vest in 4 equal instalments every six months
starting September 2020. Unexercised options shall expire 5 years from the effective date. |
During
the nine and three-month period ended September 30,2022 and 2021, an amount of $7
and $10,
and none
and $3
respectively, were recorded by the Company as
stock-based equity awards with respect to Consultant 14.
Stock
Option Plan for Employees:
In
March 2017, the Company adopted the My Size, Inc. 2017 Equity Incentive Plan (the “2017 Employee Plan”) pursuant to which
the Company’s Board of Directors may grant stock options to officers and key employees. The total number of options which may be
granted to directors, officers, employees under this plan, is limited to 5,770,000 options. Stock options can be granted with an exercise
price equal to or less than the stock’s fair market value at the date of grant.
On
May 25, 2020, the compensation committee of the Board of Directors of the Company reduced the exercise price of outstanding options of
employees and directors of the Company for the purchase of an aggregate of 140,237
shares of common stock of the Company (with exercise
prices ranging between $18.15
and $9.15)
to $1.04
per share, which was the closing price for the
Company’s common stock on May 22, 2020, and extended the term of the foregoing options for an additional one year from the original
date of expiration. The incremental compensation cost resulting from the repricing was $53,
and the expenses during the nine-month period ended September 30, 2022 and 2021 were $2
and $1.
On
August 10, 2020, the Company’s shareholders approved an increase in the shares available for issuance under the 2017 Employee Plan
from 200,000 to 1,450,000 shares. As a result, and pursuant to approval of the Company’s compensation committee that was contingent
on the foregoing shareholder approval, the number of shares available for issuance under the Company’s 2017 Consultant Incentive
Plan was reduced from 466,667 to 216,667 shares. On December 30, 2021, the Company’s shareholders approved an increase in the shares
available for issuance under the 2017 Equity Incentive Plan from 1,450,000 shares to 5,770,000 shares.
On
September 29, 2022, the Compensation Committee of the Company approved grants of restricted share awards under the Company’s
2017 Equity Incentive Plan to Ronen Luzon (CEO), Or Kles (CFO), Billy Pardo (COO), Ilia Turchinsky (CTO) and Ezequiel Javier
Brandwain (CCO), pursuant to which were issued 2,500,000
restricted shares, 600,000
restricted shares, 600,000
restricted shares, 400,000
restricted shares and 300,000
restricted shares, respectively. Each restricted share awarded under section 102 Capital Gain Restricted Stock Award Agreement (the
“Agreement”). The
restricted shares shall vest in three equal installments on January 1, 2023, January 1, 2024 and January 1, 2025 for Ronen Luzon, Or
Kles, Billy Pardo and Ilia Turchinsky and on January 27, 2023, January 27, 2024 and January 27, 2025 for Ezequiel Javier Brandwain,
conditioned upon continuous employment with the Company, and subject to accelerated vesting upon a change in control of the
Company.
On the same day, the Company
granted five-year
options to purchase up to 250,000
ordinary shares to other employees of the Company at an exercise price of $0.21
per share. The options vest in over three years in three equal portions from the vesting commencement date.
The
fair value of each option award is estimated on the date of grant using the Binomial option-pricing model that used the weighted average
assumptions in the following table. The risk free rate for the expected term of the option is based on the U.S. Treasury yield curve
in effect at the time of grant.
Schedule of Fair Value
Assumptions of Stock Options
| |
2022 grants | |
Dividend yield | |
| 0 | % |
Expected volatility | |
| 96.52 | % |
Risk-free interest | |
| 4.06 | % |
Contractual term of up to (years) | |
| 5 | |
Suboptimal exercise multiple (NIS) | |
| 5 | |
During
the nine and three-month period ended September 30, 2022, the Company granted 4,650,000 restricted stock and stock options under the
2017 Employee Plan, no options were exercised and options to purchase 51,873 shares
of common stock, expired.
The
total stock option compensation expense during the nine and three-month period ended September 30, 2022 and 2021 which was recorded was
$53 and $234, and $9 and $312, respectively.
MY
SIZE, INC. AND ITS SUBSIDIARIES
Notes
to Condensed Consolidated Interim Financial Statements (Unaudited)
U.S.
dollars in thousands (except share data and per share data)
Note
5 - Contingencies and Commitments
|
a. |
On
August 7, 2018, the Company commenced an action against North Empire LLC (“North Empire”) in the Supreme Court of the
State of New York, County of New York for breach of a Securities Purchase Agreement (the “Agreement”) in which it is
seeking damages in an amount to be determined at trial, but in no event less than $616
thousands. On August 2, 2018, North Empire filed a Summons with Notice against the Company, also in the same Court, in which they
allege damages in an amount of $11.4
million arising from an alleged breach of the Agreement. On September 6, 2018 North Empire filed a Notice of Discontinuance of the
action it had filed on August 2, 2018. On September 27, 2018, North Empire filed an answer and asserted counterclaims in the action
commenced by the Company against them, alleging that the Company failed to deliver stock certificates to North Empire causing damage
to North Empire in the amount of $10,958,589.
North Empire also filed a third-party complaint against the Company’s CEO and now former Chairman of the Board asserting
similar claims against them in their individual capacities. On October 17, 2018, the Company filed a reply to North Empire’s
counterclaims. On November 15, 2018, the Company’s CEO and now former Chairman of the Board filed a motion to dismiss North
Empire’s third-party complaint. On January 6, 2020, the Court granted the motion and dismissed the third-party complaint.
Discovery has been completed and both parties have filed motions for summary judgment in connection with the claims and
counterclaims. On December 30, 2021, the Court denied both My Size and North Empire’s motions for summary judgment, arguing
there were factual issues to be determined at trial. On January 26, 2022, the Company filed a notice of appeal of the summary
judgment decision. The Company filed its appellant brief on or about October 26, 2022. On February 3, 2022, the Company filed a
motion to reargue the Court’s decision denying the Company’s motion for summary judgment. On or about March 31, 2022,
North Empire filed its opposition papers to the Company’s motion to reargue. On or about September 12, 2022 the Court issued
its decision and order denying the Company’s motion to reargue. North Empire is due to file its opposing brief on or about December 7, 2022.
The
Company believes it is more likely than not that the counterclaims will be denied. |
|
|
|
|
b. |
On
July 5, 2021, the Company was served with a legal complaint filed by Fidelity Venture Capital Ltd. and Dror Atzmon in the Magistrate’s
Court in Tel Aviv for a monetary award in an amount of NIS 1,436,679 (approximately $450) and a declaratory relief. The plaintiffs
allege that the Company breached its contractual obligations to pay them for services allegedly rendered to the Company by the plaintiffs
under a certain consulting agreement dated July 2, 2014, in an amount of NIS 819,000 (approximately $256). Additionally, the plaintiffs
allege that the Company should compensate them for losses allegedly incurred by them following their investment in the Company’s
shares issued under a certain private offering. In the alternative, the plaintiffs move that the court will declare the investment
agreement void with full restitution of plaintiffs’ original investment in an amount of NIS 1,329,650 (approximately $415).
The Company filed its statement of defense on October 25, 2021. The first court preliminary hearing was held on March 1, 2022. Following
the first preliminary hearing and the Court’s comments and recommendation, the plaintiffs filed a motion to strike out the
claim without prejudice. On March 8, 2022 the Court ordered dismissal without prejudice of the claim. The Court also ruled that to
the extent the plaintiffs will not move within 7 days to revise their motion do dismiss their claim “with prejudice”,
the Company will be entitled to request an order for costs. On April 11, 2022 the Court ordered the plaintiffs to pay the Company’s
costs in the amount of NIS 15,000, within 30 days. |
MY
SIZE, INC. AND ITS SUBSIDIARIES
Notes
to Condensed Consolidated Interim Financial Statements (Unaudited)
U.S.
dollars in thousands (except share data and per share data)
Note
6 – Business Combination
Acquisition
of Orgad
On
February 7, 2022, the Company acquired 100% of the shares
and voting interests in Orgad an omnichannel e-commerce platform. The acquisition was designed
to create an additional revenue stream for the Company by becoming a direct e-commerce seller while leveraging the synergies between
MySizeID and Orgad’s e-commerce platform.
The
results of operations of Orgad have been included in the consolidated financial statements since the acquisition date of February 7,
2022. Orgad revenues included in the Company’s consolidated statement of operations from February 7, 2022 through September 30,
2022 were $1,797 and for the three-month period ended
September 30, 2022 were $685. If the acquisition
had occurred on January 1, 2021, management estimates that the consolidated pro forma revenues for the year would have been $2,768, and
the net loss would have been $2,272.
|
(a) |
Consideration
transferred |
The
following table summarizes the acquisition date fair value of each major class of consideration:
Schedule
of Fair value of the Acquisition
|
|
USD |
|
|
|
Thousands |
|
Cash
(*) |
(*) |
|
300 |
|
Issuance
of shares of common stock (1,743,781 shares) (**) |
(**) |
|
457 |
|
Total
consideration transferred |
|
|
757 |
|
|
(*) |
The
cash payment is subject to working capital adjustments. |
|
|
|
|
(**) |
Quoted
price as of the acquisition date |
In
addition, the Company agreed to pay to the former owners of Orgad, on the two-year and the three-year anniversary of the closing, $350,000
in each of these years provided that in the case of the second and third instalments certain revenue targets are met and subject further
to certain downward post-closing adjustment. Furthermore, 1,743,781 shares of common stock will be issued in eight equal quarterly instalments
until the lapse of two years from closing. Additional earn-out payments of 10% of the operating profit of Orgad for the years 2022 and
2023 will also be paid. All of these payments are subject to the former owners being actively engaged with Orgad at the date such payment
is due, and therefore were not taken as part of the consideration for the business combination.
During
the nine and three-month period ended September 30, 2022 an amount of $328 and $201 was recorded in respect of the cash instalments respectively,
and $267 and $156 in respect of stocks issuance, respectively.
|
(b) |
Identifiable assets acquired and liabilities assumed |
Under
the preliminary purchase price allocation, the Company allocated the purchase price to tangible and identified intangible assets acquired
and liabilities assumed based on the preliminary estimates of their fair values, which were determined using generally accepted valuation
techniques based on estimates and assumptions made by management at the time of the acquisition. Such estimates are subject to change
during the measurement period which is not expected to exceed one year. The purchase price allocation was not finalized duo to examination
of the net working capital of Orgad at the acquisition date. Any adjustments to the preliminary purchase price allocation identified
during the measurement period will be recognized in the period in which the adjustments are determined.
MY
SIZE, INC. AND ITS SUBSIDIARIES
Notes
to Condensed Consolidated Interim Financial Statements (Unaudited)
U.S.
dollars in thousands (except share data and per share data)
Note
6 – Business Combination (Cont.)
The
following table summarizes the preliminary fair value of assets acquired and liabilities assumed as of the acquisition date:
Schedule of Fair Value of Assets Acquired and Liabilities
| |
Thousands USD | |
Cash and Cash Equivalent | |
| 0 | |
Trade receivables | |
| 89 | |
Other receivables | |
| 239 | |
Inventory | |
| 864 | |
Fixed assets | |
| 55 | |
Long-term deposits | |
| 31 | |
Selling platform (*) | |
| 378 | |
Goodwill | |
| 268 | |
Short-term credit | |
| (181 | ) |
Trade payables | |
| (660 | ) |
Other payables | |
| (101 | ) |
Long-term loan | |
| (138 | ) |
Deferred Taxes | |
| (87 | ) |
Total net assets acquired | |
| 757 | |
|
(*) |
The
estimated useful life of the selling platform is three years. During the nine and three-month period ended September 30,2022 an
amount of $84 and $32 was recorded in respect of amortization expenses. |
|
(c) |
Acquisition-related
costs |
The
Company incurred transaction costs of approximately $55 and none during the nine-month and three-month period ended September 30, 2022
which were included in general and administrative expenses in the consolidated statements of income
(loss), (the total amount recorded during the first quarter of the year).
MY
SIZE, INC. AND ITS SUBSIDIARIES
Notes
to Condensed Consolidated Interim Financial Statements (Unaudited)
U.S.
dollars in thousands (except share data and per share data)
Note
7 – Operating Segments
As
a result of the business combination in the reporting period (see note 6), the Company has two reportable segments: (i) fashion and equipment
e-commerce platform, and (ii) SaaS based innovative artificial intelligence driven measurement solutions. The fashion and equipment e-commerce
platform which represent Orgad’s activity that was acquired by the Company, mainly operates on Amazon. The SaaS based innovative
artificial intelligence driven measurement solutions, or SaaS Solutions operating segment consists of My Size Inc and My Size Israel.
Information
related to the operations of the Company’s reportable operating segments is set forth below:
Schedule
of Reportable Operating Segments
| |
Fashion and equipment e-commerce platform | | |
SaaS Solutions | | |
Total | |
For the nine months ended September 30, 2022 | |
| | | |
| | | |
| | |
Revenue | |
| 1,797 | | |
| 134 | | |
| 1,931 | |
Operating (loss) income | |
| (215 | ) | |
| (5,517 | ) | |
| (5,732 | ) |
| |
| | | |
| | | |
| | |
For the three months ended September 30, 2022 | |
| | | |
| | | |
| | |
Revenue | |
| 685 | | |
| 41 | | |
| 726 | |
Operating (loss) income | |
| (286 | ) | |
| (1,689 | ) | |
| (1,975 | ) |
|
|
Fashion
and equipment e-commerce platform |
|
|
SaaS
Solutions |
|
For
September 30, 2022: |
|
|
|
|
|
|
|
|
Assets |
|
|
1,697 |
|
|
|
6,494 |
|
Note 8 – Significant events during the reporting
period
| 1. | In July 2022, Amazon deactivated Orgad’s Amazon U.S. store as a
result of complaints submitted due to an error in the listed manufacturer of certain products on Orgad’s store. Orgad resolved
the complaints and the account was reinstated during September. During the deactivation period, Orgad generated revenues through
other sales channels. |
| 2. | In August 2022, the Company established a joint venture
(“JV”) in Brazil with Santista Têxtil. The Company holds 51% and Santista Têxtil holds 49% of the JV. The
purpose of the JV is to serve the Brazilian market according to the business plan that was set. Both parties agree to make an initial investment in the JV of 1 million
BRL per the holding percentage. As of the reporting date, the JV is in process of establishing its operation. |
Note
9 – Subsequent events
On October 7, 2022, the Company entered into Share Purchase Agreement
(the “Agreement”) with the five shareholders of Naiz Fit (the “Sellers”), pursuant to which the Sellers agreed to
sell to the Company all of the issued and outstanding shares of Naiz Bespoke Technologies, S.L., a limited liability company incorporated
under the laws of Spain (“Naiz”). The acquisition of Naiz was completed on October 11, 2022.
In consideration of the purchase
of the shares of Naiz, the agreement provides that the Sellers are entitled to receive (i) an aggregate amount of 6,000,000
shares (the “Equity Consideration”) of the Company’s common stock (the “Shares”), representing in the
aggregate, immediately prior to the issuance of such shares at the closing of the transaction, not more than 19.9%
of the issued and outstanding Shares and (ii) up to US$2,050,000
in cash (the “Cash Consideration”).
The Company shall make an additional
cash payment (the “Shortfall Value”) of $459,240 to the Sellers within 45 days of the Company’s receipt of Naiz’s
2025 audited financial statements; provided that certain revenue targets are met.
The Cash Consideration will be paid to the
Sellers in five installments, according to the following payment schedule: (i) US$500,000 at closing, (ii) up to US$500,000 within 45
days of the Company’s receipt of Naiz’s 2022 audited financial statements, (iii) up to US$350,000 within 45 days of the Company’s
receipt of Naiz’s unaudited financial statements for the six months ended June 30, 2023, (iv) up to US$350,000 within 45 days of
the Company’s receipt of Naiz’s unaudited financial statements for the six months ended December 31, 2023, and (v) up to US$350,000
within 45 days of the Company’s receipt of Naiz’s 2024 audited financial statements; provided that in the case of the second,
third, fourth and fifth installments certain revenue targets are met.
The payment of the second, third,
fourth and fifth cash installments are further subject to the continuing employment or involvement of two of the shareholders which
holds key position by or with Naiz at the date such payment is due (except if a Key Person is terminated from Naiz due to a Good
Reason (as defined in the Agreement).
The required information for purchase price allocation in accordance with
the FASB ASC Topic 805 is not fully presented because the initial accounting of the business combination not yet completed as of the date
of the financial statements, due to the short period since acquisition and since the acquiree accounting records are not yet final.
Item
2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The
following discussion and analysis provide information that we believe to be relevant to an assessment and understanding of our results
of operations and financial condition for the periods described. This discussion should be read together with our condensed consolidated
interim financial statements and the notes to the financial statements, which are included in this Quarterly Report on Form 10-Q. This
information should also be read in conjunction with the information contained in our Annual Report on Form 10-K for the year ended December
31, 2021, filed with the Securities and Exchange Commission on March 31, 2022, or the Annual Report, including the consolidated annual
financial statements as of December 31, 2021, and their accompanying notes included therein.
This
Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of
1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements in this Quarterly
Report on Form 10-Q about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical
facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as
“believe,” “will,” “expect,” “anticipate,” “estimate,” “intend,”
“plan” and “would.” For example, statements concerning financial condition, possible or assumed future results
of operations, growth opportunities, industry ranking, plans and objectives of management, markets for our common stock and future management
and organizational structure are all forward-looking statements. Forward-looking statements are not guarantees of performance. They involve
known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements
to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement.
Any
forward-looking statements are qualified in their entirety by reference to the risk factors discussed throughout this Quarterly Report
on Form 10-Q. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or
projections contained in the forward-looking statements include but are not limited to:
|
● |
our
history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable
terms, or at all; |
|
|
|
|
● |
our
ability to continue as a going concern; |
|
|
|
|
● |
risks
related to the COVID-19 pandemic; |
|
|
|
|
● |
the
new and unproven nature of the measurement technology markets; |
|
|
|
|
● |
our
ability to achieve customer adoption of our products; |
|
|
|
|
● |
our
dependence on assets we purchased from a related party and the risk that such assets may in the future be repurchased; |
|
|
|
|
● |
our
ability to enhance our brand and increase market awareness; |
|
|
|
|
● |
our
ability to introduce new products and continually enhance our product offerings; |
|
|
|
|
● |
the
success of our strategic relationships with third parties; |
|
|
|
|
● |
information
technology system failures or breaches of our network security; |
|
|
|
|
● |
competition
from competitors; |
|
|
|
|
● |
our
reliance on key members of our management team; |
|
|
|
|
● |
current
or future litigation; and |
|
|
|
|
● |
the
impact of the political and security situation in Israel on our business. |
The
foregoing list sets forth some, but not all, of the factors that could affect our ability to achieve results described in any forward-looking
statements. You should read this Quarterly Report on Form 10-Q and the documents that we reference herein and have filed as exhibits
to the Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different
from what we expect. You should assume that the information appearing in this Quarterly Report on Form 10-Q is accurate as of the date
hereof. Because the risk factors referred to on page 12 of our Annual Report, could cause actual results or outcomes to differ materially
from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking
statements. Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to
update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the
occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict which factors will
arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors,
may cause actual results to differ materially from those contained in any forward-looking statements.
Unless
the context otherwise requires, all references to “we,” “us,” “our” or “the Company”
in this Quarterly Report on Form 10-Q are to My Size, Inc. a Delaware corporation, and its subsidiaries, including MySize Israel
2014 Ltd, Topspin Medical (Israel) Ltd, Orgad International Marketing Ltd., or Orgad, My Size LLC and Naiz Bespoke Technologies,
S.L taken as a whole.
Overview
We
are a creator of mobile device measurement solutions that has developed innovative solutions designed to address shortcomings in multiple
verticals, including the e-commerce fashion/apparel, shipping/parcel and do it yourself, or DIY, industries. Utilizing our sophisticated
algorithms within our proprietary technology, we can calculate and record measurements in a variety of novel ways, and most importantly,
increase revenue for businesses across the globe.
Our
solutions can be utilized to accurately take measurements of a variety of items via a mobile device. By downloading the application to
a smartphone, the user is then able to run the mobile device over the surface of an item the user wishes to measure. The information
is then automatically sent to a cloud-based server where the dimensions are calculated through our proprietary algorithms, and the accurate
measurements (+ or - 2 centimeters) are then sent back to the user’s mobile device. We believe that the commercial applications
for this technology are significant in many areas.
Currently,
we are mainly focusing on the e-commerce fashion/apparel industry. In addition, our solutions address the shipping/parcel and DIY uses
markets.
While
we rollout our products to major retailers and apparel companies, there is a lead time for new customers to ramp up before we can recognize
revenue. This lead time varies between customers, especially when the customer is a tier 1 retailer, where the integration process may
take longer. Generally, first we integrate our product into a customer’s online platform, which is followed by piloting and implementation,
and, assuming we are successful, commercial roll-out, all of which takes time before we expect it to impact our financial results in
a meaningful way. While we have begun generating initial sales revenue, we do not expect to generate meaningful revenue during the upcoming
quarters. Because of the numerous risks and uncertainties associated with the success of our market penetration and our dependence on
the extent to which MySizeID is adopted and utilized, we are unable to predict the extent to which we will recognize revenue. We may
be unable to successfully develop or market any of our current or proposed products or technologies, those products or technologies may
not generate any revenues, and any revenues generated may not be sufficient for us to become profitable or thereafter maintain profitability.
Orgad
Acquisition
On
February 7, 2022, My Size Israel 2014 Ltd, or My Size Israel, entered into a Share Purchase Agreement, or the Orgad Agreement, with Amar
Guy Shalom and Elad Bretfeld, or the Orgad Sellers, pursuant to which the Orgad Sellers agreed to sell to My Size Israel all of the issued
and outstanding equity of Orgad.
Orgad
operates an omnichannel e-commerce platform engaged in online retailing in the global market. It operates as a third-party seller on
Amazon.com, eBay and others. Orgad currently manages more than 1,000 stock-keeping units, or SKUs, mainly in fashion, apparel and shoes,
but is capable of managing tens of thousands of SKUs.
The
Orgad Sellers are the sole title and beneficial owners of 100% of the shares of Orgad. In consideration of the shares of Orgad, the Orgad
Sellers are entitled to receive (i) up to $1,000,000 in cash, or the Orgad Cash Consideration, (ii) an aggregate of 2,790,049 shares,
or the Orgad Equity Consideration, of our common stock, and (iii) earn-out payments of 10% of the operating profit of Orgad for the years
2022 and 2023. The transaction closed on the same day.
The
Orgad Cash Consideration is payable to the Orgad Sellers in three installments, according to the following payment schedule: (i) $300,000
which we paid upon closing, (ii) $350,000 payable on the two-year anniversary of the closing, and (iii) $350,000 payable on the three-year
anniversary of the closing, provided that in the case of the second and third installments certain revenue targets are met and subject
further to certain downward post-closing adjustment.
The
Equity Consideration is payable to the Orgad Sellers according to the following payment schedule: (i) 1,395,025 shares were issued at
closing, and (ii) 1,395,024 shares will be issued in eight equal quarterly installments until the lapse of two years from closing, subject
to certain downward post-closing adjustment.
The
payment of the second and third cash installments, the equity installments and the earn out are further subject in each case to the Orgad
Sellers being actively engaged with Orgad at the date such payment is due (except if the Orgad Sellers resign due to reasons relating
to material reduction of salary or adverse change in their position with Orgad or its affiliates).
In
connection with the Orgad Agreement, each of the Orgad Sellers entered into employment agreements with Orgad and six-month lock-up agreements
with us.
Naiz
Bespoke Technologies Acquisition
On
October 7, 2022, My Size, Inc., or My Size, entered into a Share Purchase Agreement, or the Naiz Agreement, with Borja Cembrero Saralegui,
or Borja, Aritz Torre Garcia, or Aritz, Whitehole, S.L., or Whitehole, Twinbel, S.L., or Twinbel and EGI Acceleration, S.L., or EGI.
Each of Borja, Aritz, Whitehole, Twinbel and EGI shall be referred to as the Naiz Sellers herein. Pursuant to the Naiz Agreement, the
Naiz Sellers agreed to sell to My Size all of the issued and outstanding equity of Naiz, a limited liability company incorporated under
the laws of Spain. The acquisition of Naiz was completed on October 11, 2022.
In
consideration of the purchase of the shares of Naiz, the Naiz Agreement provided that the Naiz Sellers are entitled to receive (i) an
aggregate of 6,000,000 shares, or the Naiz Equity Consideration, of My Size common stock, or the Shares, representing in the aggregate,
immediately prior to the issuance of such shares at the closing of the transaction, not more than 19.9% of the issued and outstanding
Shares and (ii) up to US$2,050,000 in cash, the Naiz Cash Consideration.
The
Naiz Equity Consideration was issued to the Naiz Sellers at closing of the transaction of which 2,365,800 shares of My Size common stock
were issued to Whitehole constituting 6.6% of our outstanding shares following such issuance. The Naiz Agreement also provides that,
in the event that the actual value of the Naiz Equity Consideration (based on the average closing price of the Shares on the Nasdaq Capital
Market over the 10 trading days prior to the closing of the transaction, or the Equity Value Averaging Period) is less than US$1,650,000,
My Size shall make an additional cash payment, or the Shortfall Value to the Naiz Sellers within 45 days of our receipt of Naiz’s
2025 audited financial statements; provided that certain revenue targets are met. Following the Equity Value Averaging Period, it was
determined that the Shortfall Value is US$459,240.
The
Naiz Cash Consideration is payable to the Naiz Sellers in five installments, according to the following payment schedule: (i) US$500,000
at closing, (ii) up to US$500,000 within 45 days of My Size’s receipt of Naiz’s 2022 audited financial statements, (iii)
up to US$350,000 within 45 days of My Size’s receipt of Naiz’s unaudited financial statements for the six months ended June
30, 2023, (iv) up to US$350,000 within 45 days of My Size’s receipt of Naiz’s unaudited financial statements for the six
months ended December 31, 2023, and (v) up to US$350,000 within 45 days of My Size’s receipt of Naiz’s 2024 audited financial
statements; provided that in the case of the second, third, fourth and fifth installments certain revenue targets are met.
The
payment of the second, third, fourth and fifth cash installments are further subject to the continuing employment or involvement of Borja
and Aritz, or the Key Persons, by or with Naiz at the date such payment is due (except if a Key Person is terminated from Naiz due to
a Good Reason (as defined in the Naiz Agreement).
The
Naiz Agreement contains customary representations, warranties and indemnification provisions. In addition, the Naiz Sellers will be subject
to non-competition and non-solicitation provisions pursuant to which they agree not to engage in competitive activities with respect
to My Size’s business.
In
connection with the Naiz Agreement, (i) each of the Naiz Sellers entered into six-month lock-up agreements, or the Lock-Up Agreement,
with My Size, (ii) Whitehole, Twinbel and EGI entered into a voting agreement, or the Voting Agreement, with My Size and (iii) each of
the Key Persons entered into employment agreements and services agreements with Naiz.
The
Lock-Up Agreement provides that each Naiz Seller will not, for the six-month period following the closing of the transaction, (i) offer,
pledge, sell, contract to sell, sell any option, warrant or contract to purchase, purchase any option, warrant or contract to sell, grant
any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Shares or any securities convertible
into or exercisable or exchangeable for Shares in each case, that are currently or hereafter owned of record or beneficially (including
holding as a custodian) by such Naiz Seller, or publicly disclose the intention to make any such offer, sale, pledge, grant, transfer
or disposition; or (ii) enter into any swap, short sale, hedge or other agreement that transfers, in whole or in part, any of the economic
consequences of ownership of such Naiz Seller’s Shares regardless of whether any such transaction described in clause (i) or this
clause (ii) is to be settled by delivery of Shares or such other securities, in cash or otherwise. The Lock-Up Agreement also contains
an additional three-month “dribble-out” provision that provides following the expiration of the initial six-month lock-up
period, without My Size’s prior written consent (which My Size shall be permitted to withhold at its sole discretion), each Naiz
Seller shall not sell, dispose of or otherwise transfer on any given day a number of Shares representing more than the average daily
trading volume of the Shares for the rolling 30 day trading period prior to the date on which such Seller executes a trade of the Shares.
The
Voting Agreement provides that the voting of any Shares held by each of Whitehole, Twinbel and EGI, or the Naiz Acquisition Stockholders,
will be exercised exclusively by a proxy designated by My Size’s board of directors from time to time, or the Proxy, and that each
Naiz Acquisition Stockholder will irrevocably designate and appoint the then-current Proxy as its sole and exclusive attorney-in-fact
and proxy to vote and exercise all voting right with respect to the Shares held by each Naiz Acquisition Stockholder. The Voting Agreement
also provides that, if the voting power held by the Proxy, taking into account the proxies granted by the Naiz Acquisition Stockholders
and the Shares owned by the Proxy, represents 20% or more of the voting power of My Size’s stockholders that will vote on an item,
or the Voting Power, then the Proxy shall vote such number of Shares in excess of 19.9% of the Voting Power in the same proportion as
the Shares that are voted by My Size’s other stockholders. The Voting Agreement will terminate on the earliest to occur of (i)
such time that such Naiz Acquisition Stockholder no longer owns the Shares, (ii) the sale of all or substantially all of the assets of
My Size or the consolidation or merger of My Size with or into any other business entity pursuant to which stockholders of My Size prior
to such consolidation or merger hold less than 50% of the voting equity of the surviving or resulting entity, (iii) the liquidation,
dissolution or winding up of the business operations of My Size, and (iv) the filing or consent to filing of any bankruptcy, insolvency
or reorganization case or proceeding involving My Size or otherwise seeking any relief under any laws relating to relief from debts or
protection of debtors.
Operations
in Russia
In
addition to our Israel operations, we have operations in Russia through our wholly owned subsidiary, My Size LLC. Specifically, we undertake
some of our sales and marketing using personnel located in Russia. To date, the invasion of Ukraine by Russia has not had a material
impact on our business.
Results
of Operations
The
table below provides our results of operations for the periods indicated.
|
|
Three months ended
September 30 |
|
|
Nine months ended
September 30 |
|
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
|
|
(dollars in thousands) |
|
|
(dollars in thousands) |
|
Revenues |
|
$ |
726 |
|
|
$ |
31 |
|
|
$ |
1,931 |
|
|
$ |
88 |
|
Cost of revenues |
|
|
(877 |
) |
|
|
- |
|
|
|
(1,607 |
) |
|
|
- |
|
Gross profit |
|
|
(151 |
) |
|
|
31 |
|
|
|
324 |
|
|
|
88 |
|
Research and development expenses |
|
|
(350 |
) |
|
|
(462 |
) |
|
|
(1,152 |
) |
|
|
(3,842 |
) |
Sales and marketing |
|
|
(672 |
) |
|
|
(521 |
) |
|
|
(2,526 |
) |
|
|
(1,798 |
) |
General and administrative |
|
|
(802 |
) |
|
|
(1,074 |
) |
|
|
(2,378 |
) |
|
|
(2,303 |
) |
Operating loss |
|
|
(1,975 |
) |
|
|
(2,026 |
) |
|
|
(5,732 |
) |
|
|
(7,855 |
) |
Financial income (expenses), net |
|
|
(51 |
) |
|
|
18 |
|
|
|
(198 |
) |
|
|
50 |
|
Net loss |
|
$ |
(2,026 |
) |
|
$ |
(2,008 |
) |
|
$ |
(5,930 |
) |
|
$ |
(7,805 |
) |
Nine
and Three Months Ended September 30, 2022 Compared to Nine and Three Months Ended September 30, 2021
Revenues
We started to generate revenue in 2019 and we expect to incur additional
losses to increase our sales and marketing efforts and to perform further research and development activities. Our revenues for the nine
months ended September 30, 2022 amounted to $1,931,000 compared to $88,000 for the nine months ended September 30, 2021. Our revenues
for the three months ended September 30, 2022 amounted to $726,000 compared to $31,000 for the three months ended September 30, 2021.
The increase was primarily attributable to $1,797,000 in revenue generated from Orgad from February 7, 2022, the date of closing of the
Orgad acquisition, or the Acquisition Date, through to the end of the third quarter 2022 and to $685,000 in revenue generated from Orgad
for the three months ended September 30, 2022.
Cost
Of Revenues
Our
cost of revenues expenses for the nine and three months ended September 30, 2022 amounted to $1,607,000 and $877,000, respectively,
compared to none for the nine and three months ended September 30, 2021. The cost of revenues includes cash and equity liabilities
expenses in the amount of $149,000 and $89,000 for the nine and three months ended September 30, 2022 respectively. The increase in
comparison with the corresponding period was due to the cost of goods of the revenues generated from Orgad’s
operations.
Research
and Development Expenses
Our
research and development expenses for the nine months ended September 30, 2022 amounted to $1,152,000 compared to $3,842,000 for the
nine months ended September 30, 2021. The decrease in comparison with the corresponding period primarily resulted from share-based
payment in the amount of $2,618,000 that was recorded in the corresponding period attributed
to the share issuance to Shoshana Zigdon under the Amendment to Purchase Agreement dated May 26, 2021, and a
decrease in shared based expenses to employees.
Our
research and development expenses for the three months ended September 30, 2022 amounted to $350,000 compared to $462,000 for the three
months ended September 30, 2021. The decrease in comparison with the corresponding period primarily resulted from share-based payment
to employees.
Sales
and Marketing Expenses
Our
sales and marketing expenses for the nine months ended September 30, 2022 amounted to $2,526,000 compared to $1,798,000 for the nine
months ended September 30, 2021. The increase in comparison with the corresponding period was mainly due to the hiring of new employees
and expenses associated with Orgad activities, offset by a reduction in share-based payment expenses
to employees and consultants.
Our
sales and marketing expenses for the three months ended September 30, 2022 amounted to $672,000 compared to $521,000 for the three months
ended September 30, 2021. The increase in comparison with the corresponding period was mainly due to expenses associated with Orgad activities,
offset by a reduction in share-based payment expenses to employees and consultants.
General
and Administrative Expenses
Our
general and administrative expenses for the nine months ended September 30, 2022 amounted to $2,378,000 compared to $2,303,000 for the
nine months ended September 30, 2021. The increase in comparison with the corresponding period was mainly due to expenses associated
with Orgad activities offset by a decrease in insurance expenses and professional services expenses.
Our
general and administrative expenses for the three months ended September 30, 2022 amounted to $802,000 compared to $1,074,000 for the
three months ended September 30, 2021. The decrease in comparison with the corresponding period was mainly due to a decrease in insurance
offset by an increase in expenses associated with Orgad activities.
Operating
Loss
As
a result of the foregoing, for the nine months ended September 30, 2022, our operating loss was $5,732,000 a decrease of $2,123,000 compared
to our operating loss for the nine months ended September 30, 2021 of $7,855,000.
As a result of the foregoing,
for the three months ended September 30, 2022, our operating loss was $1,975,000 a decrease of $51,000 compared to our operating loss
for the three months ended September 30, 2021 of $2,026,000.
Financial
Income (Expenses), Net
Our
financial expense, net for the nine months ended September 30, 2022 amounted to $198,000 compared to financial income of $50,000 for
the nine months ended September 30, 2021. During the nine months ended September 30, 2022, we had financial expenses mainly from exchange
rate differences and revaluation of investment in marketable securities whereas in the corresponding period we had financial income primarily
due revaluation of investment in marketable securities.
Our
financial expense, net for the three months ended September 30, 2022 amounted to $51,000 compared to financial income of $18,000 for
the three months ended September 30, 2021. During the three months ended September 30, 2022, we had financial income mainly from exchange
rate differences and revaluation of investment in marketable securities whereas in the corresponding period we had financial expenses
primarily due revaluation of investment in marketable securities and exchange rate differences offset in income from revaluation of derivative.
Net
Loss
As
a result of the foregoing, our net loss for the nine months ended September 30, 2022 was $5,930,000, compared to a net loss of
$7,805,000 for the nine months ended September 30, 2021. The decrease in the net loss was mainly due to the reasons mentioned
above.
As
a result of the foregoing, our net loss for the three months ended September 30, 2022 was $2,026,000, compared to a net loss of
$2,008,000 for the three months ended September 30, 2021. The decrease in the net loss was mainly due to the reasons mentioned
above.
Liquidity
and Capital Resources
Since
our inception, we have funded our operations primarily through public and private offerings of debt and equity in the State of Israel
and in the U.S.
As
of September 30, 2022, we had cash, cash equivalents, and restricted cash of $4,622,000 compared to $10,943,000 of cash, cash equivalents
and restricted cash as of December 31, 2021. This decrease primarily resulted from our operating activities, the acquisition of Orgad,
and resources that were deployed to grow Orgad’s business.
Cash
used in operating activities amounted to $5,858,000 for the nine months ended September 30, 2022, compared to $3,984,000 for the nine
months ended September 30, 2021. The increase in cash used in operating activities was mainly due to the acquisition of Orgad and working
capital.
Net
cash used in investing activities was $327,000 for the nine months ended September 30, 2022, compared to cash provided by investing activities
of $172,000 for the nine months ended September 30, 2021. The increase from the corresponding period was mainly due to the acquisition
of Orgad offset by changes in restricted deposits that occurred in the nine months ended September 30, 2022.
Net
cash used in financing activities was $39,000 for the nine months ended September 30, 2022, compared to cash provided by financing activities
of $5,857,000 for the nine months ended September 30, 2021. The cash flow from financing activities for the nine months ended September
30, 2021 resulted from the public offerings that occurred in January 2021 and March 2021 and from proceeds that were received from an
investor for warrants that were exercised.
We
do not have any material commitments for capital expenditures during the next twelve months.
We
expect that we will continue to generate losses and negative cash flows from operations for the foreseeable future. Based on the projected
cash flows and cash balances as of September 30, 2022, we believe our existing cash will be sufficient to fund operations for a period
less than 12 months. As a result, there is substantial doubt about our ability to continue as a going concern. We will need to raise
additional capital, which may not be available on reasonable terms or at all. Additional capital would be used to accomplish the following:
|
● |
finance
our current operating expenses; |
|
|
|
|
● |
pursue
growth opportunities; |
|
|
|
|
● |
hire
and retain qualified management and key employees; |
|
|
|
|
● |
respond
to competitive pressures; |
|
|
|
|
● |
comply
with regulatory requirements; and |
|
|
|
|
● |
maintain
compliance with applicable laws. |
Current
conditions in the capital markets are such that traditional sources of capital may not be available to us when needed or may be available
only on unfavorable terms. Our ability to raise additional capital, if needed, will depend on conditions in the capital markets, economic
conditions, the impact of the COVID-19 pandemic, the Russian invasion of Ukraine, and a number of other factors, many of which are outside
our control, and on our financial performance. Accordingly, we cannot assure you that we will be able to successfully raise additional
capital at all or on terms that are acceptable to us. If we cannot raise additional capital when needed, it may have a material adverse
effect on our business, results of operations and financial condition.
To
the extent that we raise additional capital through the sale of equity or convertible debt securities, the issuance of such securities
could result in substantial dilution for our current stockholders. The terms of any securities issued by us in future capital transactions
may be more favorable to new investors, and may include preferences, superior voting rights and the issuance of warrants or other derivative
securities, which may have a further dilutive effect on the holders of any of our securities then-outstanding. We may issue additional
shares of our common stock or securities convertible into or exchangeable or exercisable for our common stock in connection with hiring
or retaining personnel, option or warrant exercises, future acquisitions or future placements of our securities for capital-raising or
other business purposes. The issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may
cause the market price of our common stock to decline and existing stockholders may not agree with our financing plans or the terms of
such financings. In addition, we may incur substantial costs in pursuing future capital financing, including investment banking fees,
legal fees, accounting fees, securities law compliance fees, printing and distribution expenses and other costs. We may also be required
to recognize non-cash expenses in connection with certain securities we issue, such as convertible notes and warrants, which may adversely
impact our financial condition. Furthermore, any additional debt or equity financing that we may need may not be available on terms favorable
to us, or at all. If we are unable to obtain such additional financing on a timely basis, we may have to curtail our development activities
and growth plans and/or be forced to sell assets, perhaps on unfavorable terms, or we may have to cease our operations, which would have
a material adverse effect on our business, results of operations and financial condition.
We
have not entered into any transactions with unconsolidated entities in which we have financial guarantees, subordinated retained interests,
derivative instruments or other contingent arrangements that expose us to material continuing risks, contingent liabilities or any other
obligations under a variable interest in an unconsolidated entity that provides us with financing, liquidity, market risk or credit risk
support.
Critical
Accounting Estimates
Our
management’s discussion and analysis of our financial condition and results of operations is based on our financial statements,
which we have prepared in accordance with U.S. generally accepted accounting principles issued by the Financial Accounting Standards
Board, or FASB. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported
amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as
well as the reported expenses during the reporting periods. Actual results may differ from these estimates under different assumptions
or conditions.
Our
significant accounting policies were revenue from contracts with customers which are more fully described in the notes to our financial
statements appearing elsewhere in this Quarterly Report on Form 10-Q. We believe that these accounting policies discussed are critical
to our financial results and to the understanding of our past and future performance, as these policies relate to the more significant
areas involving management’s estimates and assumptions. We consider an accounting estimate to be critical if: (1) it requires us
to make assumptions because information was not available at the time or it included matters that were highly uncertain at the time we
were making our estimate; and (2) changes in the estimate could have a material impact on our financial condition or results of operations.